MLTX Chief Scientific Officer Kristian Reich Sells $935K of Stock
Kristian Reich, Chief Scientific Officer at MoonLake, sold 50,000 shares for $935,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kristian Reich, Chief Scientific Officer at MoonLake Immunotherapeutics ($MLTX), sold 50,000 shares at an average price of $18.70, worth about $935,000, on June 16, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $MLTX is up 11.8% after 1 week, up 0.2% after 1 month and down 49.7% to date (from the $18.98 close on Jun 16, 2026).
MLTX
MoonLake Immunotherapeutics
Key Points
- Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 50,000 shares on June 16, 2026, for $935,000.
- MoonLake Immunotherapeutics trades on NasdaqCM under the ticker MLTX, with a market cap of approximately $1.4 billion and a 52-week range of $5.95 to $62.75.
- Analysts maintain a positive outlook with firms like Needham and HC Wainwright & Co. rating it a 'buy', setting price targets as high as $45.
Get $MLTX trade alerts by text
We text you when insiders, Congress or big funds trade $MLTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MoonLake Immunotherapeutics alert may contain errors. Disclosures
Kristian Reich, the Chief Scientific Officer of MoonLake Immunotherapeutics, recently sold 50,000 shares of the company. The transaction took place on June 16, 2026, at an average price of $18.70 per share, totaling $935,000. This sale was part of a planned transaction.
Insider Buying and Selling at MoonLake Immunotherapeutics
Kristian Reich has been actively selling shares in recent days, with transactions on June 15 and June 17 as well. On June 15, he sold another 50,000 shares at $18.89 each, and on June 17, he sold 50,000 shares at $19.43 each. All these sales were planned. Additionally, Matthias Bodenstedt, the Chief Financial Officer, sold shares in May and April, and CEO Dr. Jorge Santos da Silva sold shares in April.
Other Institutional Activity in MoonLake Immunotherapeutics
Several institutional investors have adjusted their positions in MoonLake Immunotherapeutics. BVF Inc/IL reduced its holdings by 3,750,000 shares, ending with 16,001,284 shares valued at about $298 million. In contrast, Deep Track Capital, LP increased its stake by 1,798,792 shares, bringing its total to 6,408,863 shares worth approximately $119 million. Cormorant Asset Management, LP added 125,000 shares, achieving a total of 4,480,433 shares valued at $83.5 million. Janus Henderson Group PLC also increased its position significantly, adding 1,355,640 shares to reach a total of 3,451,628 shares worth $64.3 million.
MoonLake Immunotherapeutics Stock Up 54.9%
Shares of MoonLake Immunotherapeutics, trading on NasdaqCM under the ticker MLTX, were recently priced at $18.98. The company has a market cap of about $1.4 billion. It is a clinical-stage biotechnology firm with a beta of 1.036, indicating moderate volatility. The stock's 52-week range is between $5.95 and $62.75. It has a 50-day moving average of $17.84 and a 200-day moving average of $19.20. MoonLake's current ratio is 8.601, and its debt-to-equity ratio is 39.682, reflecting its financial health.
Analysts Set New Price Targets
Analysts have shown a positive outlook for MoonLake Immunotherapeutics. On May 12, 2026, Needham maintained its 'buy' rating with a $30 price target. HC Wainwright & Co. also maintained a 'buy' rating with a $45 target on May 11, 2026. The consensus recommendation is 'buy', with a mean price target of $27.62 based on 13 analyst opinions.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company focused on developing treatments for inflammatory skin and joint diseases. Headquartered in Zug, Switzerland, the company is led by CEO Dr. Jorge Santos da Silva. MoonLake is working on a promising treatment called Sonelokimab, targeting diseases like hidradenitis suppurativa and psoriasis. Founded in 2021, the company employs around 130 people.
Bottom Line
Kristian Reich's recent planned sales of MoonLake Immunotherapeutics shares are part of ongoing insider transactions. The company's stock is closely watched due to its innovative treatments and the volatility seen in its trading range. Investors and analysts keep an eye on such insider activity and institutional movements, as they can provide insights into the company's prospects. Remember, 13F filings and insider transactions reflect past actions and may not indicate current positions.
Related Filing Alerts
Source: Kristian Reich's Form 4 filing on $MLTX (Jun 16, 2026). Find the original filing: MLTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts